Lupin, one of the leading pharmaceutical companies in India, announced today that the company has received final approvals for its generic loestrin tablets from the United States Food and Drug Administration (USFDA).

The company said, "Received final approvals for Blisovi Fe 1/20 tablets (Norethindrone Acetate and Ethinyl Estradiol tablets USP, 1 mg/0.02 mg and Ferrous Fumarate tablets, 75 mg) and Blisovi 1.5/30 tablets (Norethindrone Acetate and Ethinyl Estradiol tablets USP, 1.5 mg/0.03 mg and Ferrous Fumarate tablets, 75 mg) from the USFDA."

These tablets are the AB rated generic equivalent of Warner Chilcott's Loestrin Fe 1/20 tablets and Loestrin Fe 1.5/30 tablets and are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

According to IMS MAT September 2015, Loestrin Fe 1/20 had US sales of USD 139.7 million while Loestrin Fe 1.5/30 had US sales of USD 55.5 million.

The company's US subsidiary, Lupin Pharmaceuticals shall commence promoting the product in the US shortly.

Shares of the company gained Rs 20.6, or 1.12%, to settle at Rs 1,860.35. The total volume of shares traded was 52,373 at the BSE (Tuesday).